BLCO vs TARS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

BLCO is the larger of the two ($7.06B market cap): the incumbent the market prices for continued execution (16.69x forward earnings, beta 0.52). TARS is the smaller challenger ($3.68B), actually pricier on forward earnings (346.91x): more room to run, but more to prove. If you believe in growth, TARS fits: analysts expect its revenue to rise 27% next year, against 6% for BLCO. If you believe in paying less for profit, BLCO fits: it trades at 16.69x forward earnings, against 346.91x for TARS.

BLCO vs TARS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBLCOTARSWhat it tells you
Market cap$7.06B$3.68BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E16.69346.91Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.520.33Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range76% of range55% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.1035.35How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: BLCO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how BLCO and TARS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BLCO and TARS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BLCO and TARS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Bausch + Lomb (BLCO) do?

Bausch + Lomb is one of the oldest and best-known names in eye health, operating across three segments: Vision Care (roughly 57% of sales, spanning contact lenses like Biotrue and lens-care solutions plus consumer eye drops such as LUMIFY and PreserVision supplements), Pharmaceuticals (around 25%, led by the dry-eye drug MIEBO and international brands), and Surgical (about 18%, including intraocular lenses, phacoemulsification systems and cataract and retina instruments). Full-year 2025 revenue reached roughly $5.1 billion, trailing twelve-month revenue is now about $5.4 billion, and the company sells into the structurally growing markets of an aging population, rising myopia and expanding cataract volumes.

Full BLCO guide

What does Tarsus Pharmaceuticals (TARS) do?

Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutic eye care. Its business is anchored by XDEMVY (lotilaner ophthalmic solution 0.25%), the first and only FDA-approved treatment that directly targets the Demodex mites behind Demodex blepharitis, a common and previously under-treated eyelid condition. The company delivered roughly 400,000 bottles of XDEMVY in 2025 (up from about 163,000 in 2024) and is building a lotilaner-based pipeline that includes TP-04 for ocular rosacea and TP-05 for potential prevention of Lyme disease, with topline data for both expected in the first half of 2027. In September 2026 Tarsus completed its acquisition of privately held Alkeus Pharmaceuticals, whose lead asset, gildeuretinol acetate (ALK-001), is an oral drug in a global Phase 3 trial (NORTHSTAR) for Stargardt disease, an inherited retinal disease with no FDA-approved therapy; topline data is expected in 2029, and the deal terms were not disclosed in the closing announcement.

Full TARS guide

BLCO vs TARS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • BLCO drivers: Margin and EBITDA expansion; Pharmaceuticals and MIEBO ramp.
  • TARS drivers: XDEMVY prescription growth; Large, under-penetrated indication.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. For TARS, the overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company.

BLCO or TARS: which should you pick?

If the story you believe is BLCO's (Margin and EBITDA expansion), BLCO is the more direct way to own it; if it is TARS's (XDEMVY prescription growth), TARS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BLCO and TARS guides.

BLCO vs TARS: the full fundamentals

BLCO. BLCO is not yet profitable on a trailing GAAP basis, so investors lean on adjusted EBITDA, forward earnings and revenue growth rather than trailing multiples. At about 13 times EV/EBITDA, 16.7 times forward earnings and roughly 1.3 times sales, the stock still trades below eye-care peers such as Alcon and The Cooper Companies, a gap that reflects the Bausch Health control discount, ~$5.1 billion of debt and an interim CEO, although the post-earnings rally has narrowed it. Fourteen covering analysts average a target near $21.93, close to the November 2026 price. Q4 2026 consensus is about $1.49 billion of revenue and $0.37 of adjusted EPS.

TARS. As of November 20, 2026 TARS traded near $74.50 with a market capitalization around $3.7 billion, roughly 5.4x trailing revenue. Trailing earnings are swamped by the one-time acquired R&D charges, so sales growth, gross margin and free cash flow are the more usable anchors, and the forward P/E (about 350x on 2027 consensus EPS of $0.22) mainly shows how thin expected profit still is. The nine analysts in Yahoo Finance's sample carry a mean target near $103.44.

Headline figures (approximate, November 2026): BLCO shows revenue (ttm) ~$5.4B, revenue growth (q3 2026, yoy) ~7% reported, ~8% constant currency, q3 2026 results ~$1.375B revenue; GAAP net income $32M; adj. EPS $0.34 vs ~$0.22 est., 2026 guidance (raised october 28) revenue $5.45B-$5.55B; adj. EBITDA ex-IPR&D $1.09B-$1.14B; TARS shows revenue (ttm) ~$682M, q3 2026 xdemvy net sales ~$195M (+~64% YoY), q3 2026 net loss ~($668M) incl. ~$632M acquired IPR&D; ($0.87)/sh vs ~($1.77) est., 2026 xdemvy guidance $715M to $730M (raised Nov 3).

The bottom line: BLCO vs TARS

BLCO and TARS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BLCO and TARS exposure against your real portfolio. It is not an investment adviser.

Wondering how BLCO or TARS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Bausch + Lomb

Ask Walnut's AI anything about BLCO and see how it fits what you own.

FAQ

What is the difference between BLCO and TARS?

+

Bausch + Lomb is one of the oldest and best-known names in eye health, operating across three segments: Vision Care (roughly 57% of sales, spanning contact lenses like Biotrue and lens-care solutions plus consumer eye drops such as LUMIFY and PreserVision supplements), Pharmaceuticals (around 25%, led by the dry-eye drug MIEBO and international brands), and Surgical (about 18%, including intraocular lenses, phacoemulsification systems and cataract and retina instruments). Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutic eye care. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BLCO or TARS the better stock?

+

Neither is universally better. BLCO is the larger incumbent; TARS is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BLCO or TARS?

+

On forward P/E (as of November 2026), BLCO trades at 16.69x and TARS at 346.91x, so BLCO is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BLCO and TARS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BLCO vs TARS?

+

BLCO: The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. Bausch + Lomb carries its own meaningful leverage (about $5.1 billion of debt against roughly $513 million of cash), so rising rates or slower EBITDA growth would pressure the balance sheet. The sudden CEO change in October 2026, with an interim chief who also runs the parent, adds execution and governance questions until a permanent leader is named. The 2025 enVista recall, tied to toxic anterior segment syndrome, was estimated to weigh on 2026 revenue by roughly $78 million and could linger as a brand and litigation risk. The company is still net-loss-making on a trailing GAAP basis (about -$111 million TTM) despite the Q3 profit, the pipeline carries clinical risk (the BL1332 Phase 2 miss in November 2026), foreign exchange cost about $6 million of Q3 revenue and management trimmed its full-year currency tailwind estimate, and competition from far larger and better-capitalized rivals like Alcon, Johnson & Johnson and CooperVision is intense across every segment. TARS: The overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. In late June 2026, short-seller Culper Research alleged that XDEMVY sales depend on donations routed to a blepharitis copay fund in a way it argues may violate the federal Anti-Kickback Statute, and it claimed the true addressable market is roughly a fifth of company estimates; these are unproven allegations, but they introduce regulatory, reimbursement, and reputational uncertainty. Tarsus also depends on intellectual property licensed from Elanco, faces gross-to-net and Medicare Part D dynamics that can compress net pricing, and still runs near breakeven with a history of losses. Cheaper off-label alternatives and potential future competitors, plus binary Phase 2 pipeline readouts, round out the risk set. The Alkeus and Irenix purchases add integration and clinical risk in new therapeutic areas, already cost about $632 million in acquired R&D charges in the third quarter, and bring trial costs that will weigh on reported earnings for years; cash fell to about $310 million at the end of September. Insider share sales in September 2026 and a second-quarter EPS miss also weighed on sentiment before the third-quarter beat.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BLCO or TARS; figures are approximate and dated (as of November 2026). Verify current data before investing.